<DOC>
	<DOC>NCT01720303</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.</brief_summary>
	<brief_title>Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>HbA1c between 7.5 % and 13.0% (both inclusive) Fasting Cpeptide above or equal to 0.33 nmol/l BMI (Body Mass Index) between 25 and 32 kg/m2 (both inclusive) Medical history of treatment with insulin within the last 6 months Impaired renal function, defined as serum creatinine above to 1.7 mg/dl (150 Âµmol/l)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>